NCT05742919

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Chinese Males

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499. Which dose participant will get will be decided by chance. NNC0194-0499 is a medicine under clinical investigation. It means that the medicine has not yet been approved by the health authorities. Participant will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on stomach. The study will last for a maximum of 64 days. Participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.

Conditions

• Non-alcoholic Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	NNC0194-0499	Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
DRUG	NNC0194-0499	Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
DRUG	NC0194-0499	Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

Timeline

• Start date: 2023-02-16
• Primary completion: 2023-06-13
• Completion: 2023-06-13
• First posted: 2023-02-24
• Last updated: 2024-06-11

Locations

1 site across 1 country: China